Boston Scientific has cut its 2026 guidance, despite reporting a strong first quarter that exceeded expectations. The company's decision to lower its guidance has led to a mixed reaction, with its stock price moving in different directions. The reasons behind the guidance cut and the subsequent stock movement are unclear, with some outlets citing product-specific headwinds and others discussing potential mispricing of the stock.